Sun Pharma Advanced Research Company Limited (NSE:SPARC)

Market Cap	52.70B
Revenue (ttm)	717.70M
Net Income (ttm)	-3.43B
Shares Out	324.52M
EPS (ttm)	-10.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	588,486
Average Volume	2,138,716
Open	161.20
Previous Close	161.36
Day's Range	160.14 - 163.27
52-Week Range	109.30 - 258.00
Beta	0.41
RSI	51.56
Earnings Date	Aug 4, 2025

About NSE:SPARC

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company’s products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 409
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SPARC

Financial Performance

In 2024, NSE:SPARC's revenue was 717.70 million, a decrease of -5.00% compared to the previous year's 755.45 million. Losses were -3.43 billion, -11.55% less than in 2023.